Nasdaq

ARS Pharmaceuticals Expands neffy Access to 30 Formularies, Improving Coverage for Type 1 Allergy Patients

ARS Pharmaceuticals, Inc. has announced the addition of neffy® (epinephrine nasal spray) to the formularies of Cigna Healthcare, Navitus Health Systems, and OptumRx, expanding access to approximately ...
Verywell Health on MSN

How long do allergic reactions last?

Medically reviewed by Jurairat J. Molina, MD Key Takeaways Food allergy symptoms can start quickly after eating and may last from minutes to a couple of days.Seasonal allergy symptoms can last for ...
Nasdaq

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to ...

SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves ...
Seeking Alpha

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥ ...

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the ...